Aura Biosciences (AURA) Stock: Buy, Sell, or Hold?
AURA - Aura Biosciences, Inc. Common Stock
$6.09
0.05 (0.83%)
▲
5d:
+1.5%
30d:
-18.8%
90d:
-14.1%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When AURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AURA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AURA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AURA is currently trading at $6.09, which is considered oversold relative to its 30-day fair value range of $6.26 to $7.50.
Technical Outlook: Technically, AURA is showing sideways momentum. The price is currently testing key support at $5.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AURA scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.60 (+172.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AURA is showing sideways momentum. The price is currently testing key support at $5.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AURA scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $16.60 (+172.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.26 -
$7.50
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 172.6% below Wall St target ($16.60)
- CAUTION: Bottoming setup, but lagging the sector by 31% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$6.26 -
$7.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.95
Resistance Level
$6.54
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.01
Wall Street Target
$16.60
(+172.6%)
Share & Embed Analysis
Last updated: October 03, 2026 11:34 AM ET
Data refreshes hourly during market hours. Next update: 12:34 PM
Data refreshes hourly during market hours. Next update: 12:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Conor Kilroy
SELL
11738 shares
2026-04-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 67 BUY |
